We are a technologically innovative company focused on finding practical solutions to the health care problems of sub-Saharan Africa.
LaGray is building capacity in Ghana to develop and manufacture active pharmaceutical ingredients and seamlessly integrate these into high value finished dosage forms for the treatment of endemic diseases in sub-Saharan Africa.
Our focus is on producing effective and affordable medicines for fighting the HIV/AIDS pandemic as well as finding better treatment options for malaria and other parasitic infections, fungal infections and tuberculosis.
LaGray will be the first to manufacture APIs in West Africa and the first fully self-sufficient pharmaceuticals manufacturer in the region.
The focus of the project on local health-care needs will lead to new treatments for a number of diseases that have largely escaped attention, but have been devastating to the health and economies of the region.
LaGray is pioneering the push toward self-sufficiency in healthcare in sub-Saharan Africa.
We are dedicated to developing, manufacturing and marketing high quality branded and generic pharmaceutical products that cure disease and enhance the quality of life in Africa and beyond. We nurture a safe, healthy and creative atmosphere in which our employees respect each other and the quality of the products we manufacture. We deal fairly and truthfully with our business partners, government authorities, non-governmental organizations and the general public.
We operate in a sustainable manner, scientifically, economically, socially and environmentally. We compensate investors for their risk and are committed to continued growth and development.
We will establish ourselves as a world class, self-sufficient pharmaceutical manufacturer that fully integrates active pharmaceutical ingredient manufacturing into finished dosage form production. We will become the most valued employer, healthcare supplier, business partner and corporate citizen in the region. Our hallmark will be quality: in our products, our people and our processes.
We focus on drugs for treating serious and debilitating endemic diseases of the region. These include:
Broadly useful antiretroviral compounds and combinations with non-nucleoside reverse transcriptase inhibitors
Antiinfectives for treating opportunistic bacterial, fungal and protozoal infections, as well as respiratory tract infections.
Medications for treating bacterial, fungal, protozoal and polymicrobic topical infections.
LaGray is building a strong management team to ensure an unbridled commitment to the company’s mission. On board from the start is 37 plus years of combined experience in the major global pharmaceutical industry.
Dr. Paul A. Lartey, Ph.D., RPh. President and Chief Executive Officer
Dr. Lartey has a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and post-doctoral training in Medicinal Chemistry from Yale University. He has over 25 years of experience in research and management at Abbott Laboratories, Pharmacia & Upjohn and Pfizer. His latest position was Director of Infectious Diseases Drug Discovery Research at Pfizer. Dr. Larteyhas several patents and publications in drug discovery.
Dr. Alexandra E. Graham, Ph.D., MBA. Vice President and Chief Operating Officer
Dr Graham holds a Ph.D. in Chemistry from the University of Brighton, UK and University of Lagos, Nigeria. She has 12 years experience working for IBM and for the major global Pharmaceutical Company, Abbott Laboratories. The breadth of her experience spans analytical chemistry, quality assurance, chemical process research and recently as manager for the production of a billion dollar a year drug. Dr. Graham has several patents and publications in analytical and process chemistry